WolverHeme Happy Hour
Subscribed: 46Played: 995
Subscribe
© Bernard Marini, Anthony Perissinotti, et al.
Description
Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we'll have a few drinks!
Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.
Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.
47 Episodes
Reverse
In this special video episode, Bernie and Anthony moderate a Common Sense Oncology discussion of key trials from ASH 2025! We are joined by special guest experts from across the globe to critically appraise the abstracts and discuss how they may or may not have changed clinical practice:Dr. Eddie Cliff (Australia) - LymphomaDr. Roberta Demichelis (Mexico) - LeukemiaDr. Manni Mohyuddin (USA) - MyelomaJoin the Common Sense Oncology movement here! https://commonsenseoncology.org/get-involved/
In this episode, Anthony and Bernie are joined by a panel of experts to discuss (and debate) everyone's favorite (or most feared) hematology topic - hemophagocytic lymphohistiocytosis (HLH)! Joining us on this spicy episode are:- Justin Kaner, MD - Madeleine Ochs, PharmD, BCOP- Catherine Johnson, PharmD, BCOPHow should we manage these patients? H-Scores or HLH2004 criteria? What is the role for ruxolitinib? Emapalumab? CXCL9 levels? Grab your favorite drink and have a listen!
Anthony and Bernie are joined by special guest Jonathan Gluck, award-winning journalist and author of "An Exercise in Uncertainty: A Memoir of Illness and Hope" for a powerful conversation about living through uncertainty. Drawing on his decades-long journey with multiple myeloma, Jon reflects on the emotional, clinical, and existential uncertainties that shape living with cancer. The discussion moves beyond the patient experience to explore how uncertainty permeates everyday life, as well as oncology practice, including waiting for new therapies to become available, navigating logistical (and insurance) barriers, and interpreting evolving clinical trial data where the answers are not always clear. Jon is graciously donating a portion of the proceeds of the book to multiple myeloma research, so everyone who picks up a copy is donating to a good cause! https://www.penguinrandomhouse.com/books/760582/an-exercise-in-uncertainty-by-jonathan-gluck/
In this episode, Anthony and Bernie are joined by special guest, Dr. Justin Kaner from Weill Cornell Medicine, to discuss some of the most interesting ASH abstracts in leukemia in 2025! What abstracts should change practice? Listen to find out. Some of the abstracts discussed:PARADIGM: https://meetings-api.hematology.org/api/abstract/vmpreview/296881KMT2A Outcomes (MARROW Consortium and Othman, et al.): https://meetings-api.hematology.org/api/abstract/vmpreview/302582 and https://meetings-api.hematology.org/api/abstract/vmpreview/297333CLIA +/- Ven: https://meetings-api.hematology.org/api/abstract/vmpreview/302047FLT3i studies (and MRD): https://meetings-api.hematology.org/api/abstract/vmpreview/295719 and https://meetings-api.hematology.org/api/abstract/vmpreview/302699 and https://meetings-api.hematology.org/api/abstract/vmpreview/291322ALL GIMEMA Trial (blin + ponatinib): https://meetings-api.hematology.org/api/abstract/vmpreview/296532Menin inhibitor data
Anthony and Bernie discuss the PARADIGM study that was presented at the plenary session of ASH 2025 and whether results should change our practice. https://meetings-api.hematology.org/api/abstract/vmpreview/296881
In this study, Bernie and Anthony are joined by the majestic myeloma man Manni Mohyuddin to discuss key ASH abstracts in myeloma, including the results of the MajesTEC-3 study!
In this episode, Anthony and Bernie discuss the important role of community hematology. We discuss innovative research models, partnerships between community and academic practices, and ways to improve care for hematology patients who live near and far!
In this episode, Bernie and Anthony review the optimal management of febrile neutropenia! We talk about some historical data, optimal patient workup, proper selection of antibiotics, and a discussion of newer data regarding early antibiotic de-escalation in FN.
We're back after a summer break! In this episode, Anthony and Bernie review the optimal approach to antimicrobial prophylaxis in hematology patients. How do you best choose prophylaxis for your patients? Where are we using data and where are we just making things up? Does everyone need antifungal, antibacterial, antiviral, and anti-PJP prophylaxis? We will demystify prophylaxis guidelines for you!
In this episode, Bernie and Anthony talk about some BIG changes in cytarabine dosing in AML consolidation after a recent practice changing article. Will this change your practice? Hunault, et al. NEJM. 2025.https://evidence.nejm.org/doi/full/10.1056/EVIDoa2400326
In this episode, Bernie and Anthony are joined by the Myeloma Man Dr. Manni Mohyuddin and lymphoma expert Dr. David Russler-Germain to discuss the very recent ODAC decisions on the STARGLO (glofitamab + GemOx) and AQUILA (daratumumab for smoldering multiple myeloma) trials. Did ODAC do their due diligence, or are there double standards? There is a lot to unpack in this episode!
This is a special encore video presentation of Anthony and Bernie teaming up with the Common Sense Oncology Journal Club series to discuss the SWOG1826 and STARGLO clinical trials. Tycel Phillips, MD, and Manju Sengar, MD join Anthony and Bernie for a great discussion of the trials and how they should impact practice! Join the Common Sense Oncology movement here! https://commonsenseoncology.org/
In this episode, Bernie and Anthony are joined by 3 hematology pharmacists - James Davis, PharmD, BCOP; Victoria Nachar, PharmD, BCOP; and Justine Preedit, PharmD, BCOP - to discuss the optimal management of CRS in patients receiving bispecific antibodies!Inspired by this recent paper:https://www.nature.com/articles/s41408-025-01222-y
In this episode, Bernie and Anthony are joined by Dr. Charlie Foucar and Dr. Anand Patel to review the interesting and controversy-filled saga of gemtuzumab in AML? Should we be using this agent in AML? Tune in to find out!
In this episode, Anthony and Bernie are joined by two special guests to discuss recent updates to the use of blinatumomab in both adult and pediatric acute lymphoblastic leukemia (ALL), including the results of the AALL1731 trial and the full publication of ECOG1910.
Julia Brown, PharmD, a Pediatric Hematology/Oncology Clinical Pharmacist and Lydia Benitez, an Adult Outpatient Leukemia Clinical Pharmacist bring their unique perspectives and expertise on the proper incorporation of blinatumomab into ALL care, as well as some of the major practical nuances that will be helpful to providers across the globe!
Finally, for all of the Oncology Pharmacists in the audience, don't forget to fill out the HOPA Practice Outcomes and Professional Benchmarking Committee Survey!
AQUILA is a constellation shaped like an eagle, and also a hotly debated myeloma trial of daratumumab in smoldering multiple myeloma. In this episode, Bernie and Anthony are joined by myeloma expert Manni Mohyuddin to discuss the study's findings and whether or not they should change practice! Grab a drink and listen in for an exciting discussion.
Note: L'aquila is Italian for eagle!
AQUILA: Dimopoulos MA, et al. N Engl J Med. 2024 Dec 9. doi: 10.1056/NEJMoa2409029. Epub ahead of print. PMID: 39652675.
In this episode released just in time for the holidays, Anthony and Bernie are joined by Tycel Phillips, MD to discuss the most exciting updates from ASH 2024 in lymphoma! Pour yourself a drink and have a listen!
Some selected abstracts:
EA4151:
https://ash.confex.com/ash/2024/webprogram/Paper212973.html
Triangle Updates:
https://ash.confex.com/ash/2024/webprogram/Paper200735.html ,
https://ash.confex.com/ash/2024/webprogram/Paper201441.html
EA4181:
https://ash.confex.com/ash/2024/webprogram/Paper194641.html
ENRICH:
https://ash.confex.com/ash/2024/webprogram/Paper199710.html
inMIND:
https://ash.confex.com/ash/2024/webprogram/Paper212970.html
POLARIX Long-Term F/U:
https://ash.confex.com/ash/2024/webprogram/Paper197938.html
In this episode, Anthony and Bernie are joined by Dr. Aaron "Papa Heme" Goodman and Dr. Manni "Myeloma Man" Mohyuddin to discuss the most intriguing ASH 2024 abstracts! Should any of the research from ASH 2024 change your practice? Find out!
In this episode, Bernie and Anthony are joined by two special guest expert hematologists:
Dr. David Russler-Germain
Dr. Tycel Phillips
We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired?
Stay tuned to find out!
In this episode, Tycel Phillips, MD joins Anthony and Bernie to discuss updates in Mantle Cell Lymphoma, including the TRIANGLE study and the recently published results of glofitamab in R/R MCL.
TRIANGLE: https://pubmed.ncbi.nlm.nih.gov/38705160/
Glofitamab: https://pubmed.ncbi.nlm.nih.gov/39365960/
Comments
Download from Google Play
Download from App Store
United States